Search

Your search keyword '"Gianpaolo Nadali"' showing total 3 results
Start Over Author "Gianpaolo Nadali" Journal british journal of haematology
3 results on '"Gianpaolo Nadali"'

1. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

Author

Maria Chiara Tisi, Michelina Dargenio, for Sorveglianza Epidemiologica Infezioni nelle Emopatie, Federica Lessi, Francesca Farina, Livio Pagano, Andrea Visentin, Angelica Spolzino, Luca Laurenti, Davide Facchinelli, M. Picardi, Gianpaolo Nadali, Chiara Cattaneo, Fabio Trastulli, Luisa Verga, Francesco Marchesi, Anna Candoni, Alessandro Busca, Lucia Prezioso, Gessica Marchesini, Rosa Fanci, Marchesini, G., Nadali, G., Facchinelli, D., Candoni, A., Cattaneo, C., Laurenti, L., Fanci, R., Farina, F., Lessi, F., Visentin, A., Marchesi, F., Prezioso, L., Spolzino, A., Tisi, M. C., Trastulli, F., Picardi, M., Verga, L., Dargenio, M., Busca, A., and Pagano, L.

Subjects
Male, medicine.medical_treatment, infections, lymphoproliferative diseases, targeted therapy, Targeted therapy, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, Risk Factors, Agammaglobulinaemia Tyrosine Kinase, Medicine, Molecular Targeted Therapy, Enzyme Inhibitors, Aged, 80 and over, Bacterial Infections, Hematology, Middle Aged, Clinical Practice, Italy, Virus Diseases, 030220 oncology & carcinogenesis, Ibrutinib, Female, Idelalisib, Research Paper, medicine.medical_specialty, Lymphoproliferative disorders, Opportunistic Infections, 03 medical and health sciences, Internal medicine, Humans, In patient, Protein Kinase Inhibitors, lymphoproliferative disease, Aged, Quinazolinones, Retrospective Studies, business.industry, Adenine, Retrospective cohort study, medicine.disease, Haematological Malignancy – Clinical, Lymphoproliferative Disorders, infection, Settore MED/15 - MALATTIE DEL SANGUE, chemistry, Purines, Case-Control Studies, Frequent infections, business, Invasive Fungal Infections, 030215 immunology
Abstract

Summary We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P

Published
2020

2. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome

Author

Fabrizio Vinante, M. M. Ricetti, Cristina Tecchio, Marco Chilosi, Harald Gallati, Giovanni Pizzolo, Elisabetta Zanolin, Gianpaolo Nadali, L. Morosato, Antonella Rigo, Francesca Locatelli, and Mauro Krampera

Subjects
Adult, Male, medicine.medical_specialty, Necrosis, Myeloid, Adolescent, medicine.medical_treatment, TNF, acute myeloid leukemia, Gastroenterology, Disease-Free Survival, Receptors, Tumor Necrosis Factor, Cell surface receptor, Antigens, CD, Internal medicine, Acute lymphocytic leukemia, medicine, Biomarkers, Tumor, Humans, Receptors, Tumor Necrosis Factor, Type II, Receptor, Survival rate, Aged, Retrospective Studies, business.industry, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Prognosis, Survival Rate, Cytokine, medicine.anatomical_structure, Endocrinology, Treatment Outcome, Solubility, Leukemia, Myeloid, Receptors, Tumor Necrosis Factor, Type I, Multivariate Analysis, Tumor necrosis factor alpha, Female, medicine.symptom, business, Follow-Up Studies
Abstract

The tumour necrosis factor (TNF)/TNF-receptor (TNFR) complex plays a role in the growth of leukaemic cells. We retrospectively investigated the relationship between pretreatment serum concentration of soluble TNFR (p55- and p75-sTNFRs) and outcome in adult acute myeloid (AML 82 cases) and lymphoid (ALL 44 cases) leukaemia. Both sTNFRs were significantly higher in AML (p55-sTNFR 4.53 +/- 3.7, median 3.75; p75-sTNFR 6.51 +/- 5.25 ng/ml, median 4.72) and ALL sera (3.31 +/- 1.5, median 2.95; 5.30 +/- 2.3 ng/ml, median 4.56, respectively) than in controls (1.89 +/- 0.5, median 1.98; 2.22 +/- 0.8 ng/ml, median 2.37) (P0.01 for both sTNFRs). Fresh leukaemic cells expressed p55- and p75-sTNFRs, which were modulated and released into the supernatant (SN) following short-term in vitro culture, suggesting that in vivo sTNFRs were also leukaemia-derived. Whereas no correlation was observed between sTNFRs and outcome in ALL, in AML higher p55-sTNFR levels (3.75 ng/ml) were associated with shorter disease-free survival (DFS) (P = 0.006) and overall survival (OS) (P = 0.0004). At multivariate analysis p55-sTNFR was the most significant predictor of DFS (P = 0.006) and OS (P0.001). Our data suggest that the prognostic significance of p55-sTNFR in AML could be related to relevant biological features of AML blasts.

Published
1998

3. ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease

Author

Marco Chilosi, R. Marrocchella, C. Vincenzi, M. M. Ricetti, Fabrizio Vinante, Giovanni Pizzolo, G. Semenzato, Gianpaolo Nadali, and L. Morosato

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Lymphocyte, Intercellular Adhesion Molecule-1, Disease, Immune system, Antigens, CD, Internal medicine, medicine, Humans, Child, Aged, Hodgkin s, ICAM-1, Cell adhesion molecule, business.industry, Hematology, Middle Aged, medicine.disease, Hodgkin Disease, Lymphoma, stomatognathic diseases, Endocrinology, medicine.anatomical_structure, Solubility, Female, business, Cell Adhesion Molecules
Abstract

We investigated ICAM-1/CD54 tissue immunoreactivity and serum levels of its soluble form (sICAM-1) in patients with Hodgkin's disease (HD) at diagnosis. ICAM-1 was strongly expressed in involved tissues, and sICAM-1 serum levels were higher in HD (79 patients) than in controls (P < 0.01), and in patients with more advanced or more active disease (stages III + IV vI + II: P = 0.002; stage 'B' v 'A': P < 0.0001; 'bulky' disease v non-'bulky': P = 0.042). We suggest that tissue ICAM-1 overexpression leading to increase of circulating sICAM-1 may interfere with the lymphocyte adhesion machinery thus contributing to the well-known immune derangement of HD.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results